Document is current
Any future updates will be listed below
-
Authors
Hetzel, Sara
Hodis, Eran
Torlai Triglia, Elena
Kovacsovics, Alexander
Steinmann, Kathleen
Gnirke, Andreas
Cui, Meiying
McQuaid, Daniel
Weigert, Raha
Pohl, Georg
Muzumdar, Mandar D.
Leyvraz, Serge
Keilholz, Ulrich
Yaspo, Marie-Laure
Regev, Aviv
Kretzmer, Helene
Smith, Zachary D.
Meissner, Alexander
-
Funding
Funding for this research was provided by:
Max-Planck-Gesellschaft
G. Harold and Leila Y. Mathers Foundation
European Research Council
Max Planck Institute for Molecular Genetics
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 13 June 2025
First Online: 17 July 2025
Declarations
:
: Patients of the metastatic melanoma study were recruited in the Precision Oncology Program of the Charité Comprehensive Cancer Center (Berlin). Informed consent was obtained from all human subjects included in the study. The study was approved by the local Institutional Review Board of the Charité Universitätsmedizin Berlin (EA4/063/13, Charité Ethics Committee: Charitéplatz 1, 10117 Berlin, Germany). For other tumor types, genomic was obtained from OriGene where samples were collected under IRB approved protocols or publicly available data sets were used. Animal procedures have been approved by the IACUC of the respective organization (Massachusetts Institute of Technology, Harvard University, Beth Israel Deaconess Medical Center and Yale University).
: Not applicable.
: A.M. and Z.D.S. are inventors on a patent related to hypermethylated CGI targets in cancer. Z.D.S. and A.M. are co-founders and scientific advisors of Harbinger Health. R.W. is currently an employee of Merck KGaA. A.R. is currently an employee of Genentech. M.Y. is CSO and shareholder of Alacris Theranostics GmbH. E.H. consults for and is a shareholder of Dyno Therapeutics. The other authors declare no competing interests.
